Neuroprotective and neuro-rehabilitative effects of acute purinergic receptor P2X4 (P2X4R) blockade after ischemic stroke.
Stroke stays a number one reason behind incapacity in america. Regardless of latest advances, interventions to scale back injury and improve restoration after stroke are missing. P2X4R, a receptor for adenosine triphosphate (ATP), regulates activation of myeloid immune cells (infiltrating monocytes/macrophages and brain-resident microglia) after stroke damage.
Nonetheless, over-stimulation of P2X4Rs on account of extreme ATP launch from dying or broken neuronal cells can contribute to ischemic damage. Subsequently, we pharmacologically inhibited P2X4R to restrict the over-stimulated myeloid cell immune response and enhance each acute and power stroke restoration. We subjected 8-12-week-old female and male wild sort mice to a 60 min proper center cerebral artery occlusion (MCAo) adopted by Three or 30 days of reperfusion.
We carried out histological, RNA sequencing, behavioral (sensorimotor, nervousness, and depressive), and biochemical (Evans blue dye extravasation, western blot, quantitative PCR, and circulation cytometry) analyses to find out the acute (Three days after MCAo) and power (30 days after MCAo) results of P2X4R antagonist 5-BDBD (1 mg/kg P.O. every day x Three days submit four h of MCAo) remedy.
5-BDBD remedy considerably (p < .05) diminished infarct quantity, neurological deficit (ND) rating, ranges of cytokine interleukin-1 beta (IL-1β) and blood mind barrier (BBB) permeability within the 3-day group.
EIF3CL Recombinant Protein (Human) |
|||
RP056388 | ABM | 100 ug | Ask for price |
EIF3CL (N-term) Rabbit pAb |
|||
E2618440 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
EIF3CL (untagged)-Human eukaryotic translation initiation factor 3, subunit C-like (EIF3CL) |
|||
SC316845 | Origene Technologies GmbH | 10 µg | Ask for price |
EIF3CL ORF Vector (Human) (pORF) |
|||
ORF018797 | ABM | 1.0 ug DNA | EUR 486 |
Human EIF3CL knockout cell line |
|||
ABC-KH4695 | AcceGen | 1 vial | Ask for price |
Description: Human EIF3CL knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
EIF3CL (GFP-tagged) - Human eukaryotic translation initiation factor 3, subunit C-like (EIF3CL) |
|||
RG223143 | Origene Technologies GmbH | 10 µg | Ask for price |
Human EIF3CL knockdown cell line |
|||
ABC-KD4695 | AcceGen | 1 vial | Ask for price |
Description: Human EIF3CL knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
EIF3CL (Myc-DDK-tagged)-Human eukaryotic translation initiation factor 3, subunit C-like (EIF3CL) |
|||
RC223143 | Origene Technologies GmbH | 10 µg | Ask for price |
EIF3CL 3'UTR GFP Stable Cell Line |
|||
TU056731 | ABM | 1.0 ml | EUR 1672.8 |
EIF3CL sgRNA CRISPR Lentivector set (Human) |
|||
K0667301 | ABM | 3 x 1.0 ug | EUR 406.8 |
EIF3CL Protein Vector (Human) (pPM-C-HA) |
|||
PV075187 | ABM | 500 ng | EUR 973.2 |
EIF3CL Protein Vector (Human) (pPB-C-His) |
|||
PV075185 | ABM | 500 ng | EUR 973.2 |
EIF3CL Protein Vector (Human) (pPB-N-His) |
|||
PV075186 | ABM | 500 ng | EUR 973.2 |
EIF3CL Protein Vector (Human) (pPM-C-His) |
|||
PV075188 | ABM | 500 ng | EUR 973.2 |
EIF3CL 3'UTR Luciferase Stable Cell Line |
|||
TU006731 | ABM | 1.0 ml | EUR 1672.8 |
Lenti-ORF clone of EIF3CL (mGFP-tagged)-Human eukaryotic translation initiation factor 3, subunit C-like (EIF3CL) |
|||
RC223143L4 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti-ORF clone of EIF3CL (Myc-DDK-tagged)-Human eukaryotic translation initiation factor 3, subunit C-like (EIF3CL) |
|||
RC223143L3 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF particles, EIF3CL (mGFP-tagged)-Human eukaryotic translation initiation factor 3, subunit C-like (EIF3CL), 200ul, >10^7 TU/mL |
|||
RC223143L4V | Origene Technologies GmbH | 200 µl | Ask for price |
EIF3CL sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
K0667302 | ABM | 1.0 ug DNA | EUR 184.8 |
EIF3CL sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
K0667303 | ABM | 1.0 ug DNA | EUR 184.8 |
EIF3CL sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
K0667304 | ABM | 1.0 ug DNA | EUR 184.8 |
Lenti ORF particles, EIF3CL (Myc-DDK-tagged)-Human eukaryotic translation initiation factor 3, subunit C-like (EIF3CL), 200ul, >10^7 TU/mL |
|||
RC223143L3V | Origene Technologies GmbH | 200 µl | Ask for price |
OAAB08888-400UL - EIF3CL Antibody - N-terminal region |
|||
OAAB08888-400UL | Aviva Systems Biology | 400ul | EUR 389 |
EIF3CL (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each |
|||
SR319023 | Origene Technologies GmbH | 2 nmol | Ask for price |
EIF3CL sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
K0667305 | ABM | 3 x 1.0 ug | EUR 451.2 |
EIF3CL sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
K0667306 | ABM | 1.0 ug DNA | EUR 200.4 |
EIF3CL sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
K0667307 | ABM | 1.0 ug DNA | EUR 200.4 |
EIF3CL sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
K0667308 | ABM | 1.0 ug DNA | EUR 200.4 |
EIF3CL - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
TL321053 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
EIF3CL - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector |
|||
TR321053 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Human Eukaryotic translation initiation factor 3 subunit C-like protein (EIF3CL) ELISA Kit |
|||
abx521802-96tests | Abbexa | 96 tests | EUR 687.5 |
3`UTR clone of eukaryotic translation initiation factor 3 subunit C-like (EIF3CL) for miRNA target validation |
|||
SC202570 | Origene Technologies GmbH | 10 µg | Ask for price |
EIF3CL - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|||
TL321053V | Origene Technologies GmbH | 500 ul each | Ask for price |
Eif3c/ Rat Eif3c ELISA Kit |
|||
ELI-09630r | Lifescience Market | 96 Tests | EUR 1063.2 |
EIF2C2 |
|||
CSB-CL891731HU1 | Cusabio | 10 μg plasmid + 200μl Glycerol | Ask for price |
EIF2C2 |
|||
CSB-CL891731HU2 | Cusabio | 10 μg plasmid + 200μl Glycerol | Ask for price |
EIF2C3 |
|||
CSB-CL875700HU | Cusabio | 10 μg plasmid + 200μl Glycerol | Ask for price |
EIF2C3 Rabbit mAb |
|||
59065 | SAB | 100ul | EUR 339 |
EIF2C1 Peptide |
|||
45-525P | ProSci | 0.1 mg | EUR 405.6 |
Description: EIF2C1 Peptide |
EIF2C3 Rabbit pAb |
|||
E2381362 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
EIF2C2 Rabbit pAb |
|||
E2506802 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
EIF2C2 Rabbit pAb |
|||
E2510968 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
eIF2C3 Rabbit mAb |
|||
A19819 | Abclonal | 50μL | EUR 778.7 |
Description: A synthetic peptide corresponding to a sequence within amino acids 100-200 of human HTRA2 (O43464). |
Eif2c4 (untagged ORF) - Rat eukaryotic translation initiation factor 2C, 4 (Eif2c4), (10 ug) |
|||
RN215671 | Origene Technologies GmbH | 10 µg | Ask for price |
Eif2c2 (untagged ORF) - Rat eukaryotic translation initiation factor 2C, 2 (Eif2c2), (10 ug) |
|||
RN210245 | Origene Technologies GmbH | 10 µg | Ask for price |
EIF2C1 Antibody |
|||
39951-100ul | SAB | 100ul | EUR 468 |
EIF2C3 Antibody |
|||
39952-100ul | SAB | 100ul | EUR 468 |
EIF2C3 Antibody |
|||
DF9508 | Affbiotech | 200ul | EUR 420 |
EIF2C3 Antibody |
|||
DF9508-100ul | Affinity Biosciences | 100ul | EUR 280 |
EIF2C3 Antibody |
|||
DF9508-200ul | Affinity Biosciences | 200ul | EUR 350 |
EIF2C1 antibody |
|||
E39-10769 | EnoGene | 100ug/100ul | EUR 225 |
Description: Available in various conjugation types. |
EIF2C1 Antibody |
|||
E301712b | EnoGene | 100ug/200ul | EUR 275 |
Description: Available in various conjugation types. |
EIF2C3 Antibody |
|||
E301713 | EnoGene | 200ul | EUR 275 |
Description: Available in various conjugation types. |
EIF2C2 Antibody |
|||
E312331 | EnoGene | 200ul | EUR 275 |
Description: Available in various conjugation types. |
EIF2C3 Antibody |
|||
E19-9508-1 | EnoGene | 50ug/50ul | EUR 145 |
Description: Available in various conjugation types. |
EIF2C3 Antibody |
|||
E19-9508-2 | EnoGene | 100ug/100ul | EUR 225 |
Description: Available in various conjugation types. |
EIF2C2 antibody |
|||
70R-17042 | Fitzgerald | 50 ul | EUR 289 |
Description: Rabbit polyclonal EIF2C2 antibody |
EIF2C1 antibody |
|||
70R-21524 | Fitzgerald | 50 ul | EUR 289 |
Description: Rabbit polyclonal EIF2C1 antibody |
EIF2C3 antibody |
|||
70R-2539 | Fitzgerald | 50 ug | EUR 467 |
Description: Rabbit polyclonal EIF2C3 antibody raised against the N terminal of EIF2C3 |
EIF2C4 antibody |
|||
70R-3041 | Fitzgerald | 50 ug | EUR 467 |
Description: Rabbit polyclonal EIF2C4 antibody raised against the middle region of EIF2C4 |
EIF2C1 antibody |
|||
70R-3471 | Fitzgerald | 50 ug | EUR 467 |
Description: Rabbit polyclonal EIF2C1 antibody raised against the N terminal of EIF2C1 |
Eif2c3 antibody |
|||
70R-9606 | Fitzgerald | 50 ug | EUR 467 |
Description: Affinity purified rabbit polyclonal Eif2c3 antibody |
EIF2C3 Antibody |
|||
ABD9508 | Lifescience Market | 100 ug | EUR 525.6 |
EIF2C1 Antibody |
|||
GWB-MT589D | GenWay Biotech | 50ug | Ask for price |
EIF2C4 Antibody |
|||
GWB-MV390C | GenWay Biotech | 50ug | Ask for price |
Eif2c3 Antibody |
|||
GWB-MV397A | GenWay Biotech | 50ug | Ask for price |
EIF2C3 Antibody |
|||
GWB-MV398B | GenWay Biotech | 50ug | Ask for price |
EIF2C1 ELISA KIT|Human |
|||
EF009333 | Lifescience Market | 96 Tests | EUR 826.8 |
EIF2C3 ELISA KIT|Human |
|||
EF009334 | Lifescience Market | 96 Tests | EUR 826.8 |
EIF2C3/ Argonaute 3 |
|||
E8ET1701-26 | EnoGene | 100ul | EUR 275 |
Description: Available in various conjugation types. |
Lenti ORF particles, Eif2c4 (GFP-tagged ORF) - Rat eukaryotic translation initiation factor 2C, 4 (Eif2c4), 200ul, >10^7 TU/mL |
|||
RR215671L4V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, Eif2c2 (GFP-tagged ORF) - Rat eukaryotic translation initiation factor 2C, 2 (Eif2c2), 200ul, >10^7 TU/mL |
|||
RR210245L4V | Origene Technologies GmbH | 200 µl | Ask for price |
Eif2c4 (Myc-DDK-tagged ORF) - Rat eukaryotic translation initiation factor 2C, 4 (Eif2c4), (10 ug) |
|||
RR215671 | Origene Technologies GmbH | 10 µg | Ask for price |
Eif2c2 (Myc-DDK-tagged ORF) - Rat eukaryotic translation initiation factor 2C, 2 (Eif2c2), (10 ug) |
|||
RR210245 | Origene Technologies GmbH | 10 µg | Ask for price |
Eif2c1 ORF Vector (Rat) (pORF) |
|||
ORF066440 | ABM | 1.0 ug DNA | EUR 607.2 |
Eif2c2 ORF Vector (Rat) (pORF) |
|||
ORF066441 | ABM | 1.0 ug DNA | EUR 607.2 |
Eif2c4 ORF Vector (Rat) (pORF) |
|||
ORF066442 | ABM | 1.0 ug DNA | EUR 607.2 |
Lenti ORF particles, Eif2c4 (Myc-DDK-tagged ORF) - Rat eukaryotic translation initiation factor 2C, 4 (Eif2c4), 200ul, >10^7 TU/mL |
|||
RR215671L3V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, Eif2c2 (Myc-DDK-tagged ORF) - Rat eukaryotic translation initiation factor 2C, 2 (Eif2c2), 200ul, >10^7 TU/mL |
|||
RR210245L3V | Origene Technologies GmbH | 200 µl | Ask for price |
EIF2C2 cloning plasmid |
|||
CSB-CL891731HU1-10ug | Cusabio | 10ug | EUR 722.4 |
Description: A cloning plasmid for the EIF2C2 gene. |
EIF2C2 cloning plasmid |
|||
CSB-CL891731HU2-10ug | Cusabio | 10ug | EUR 279.6 |
Description: A cloning plasmid for the EIF2C2 gene. |
EIF2C3 cloning plasmid |
|||
CSB-CL875700HU-10ug | Cusabio | 10ug | EUR 279.6 |
Description: A cloning plasmid for the EIF2C3 gene. |
EIF2C1 ORF Vector (Human) (pORF) |
|||
ORF018785 | ABM | 1.0 ug DNA | EUR 486 |
EIF2C4 ORF Vector (Human) (pORF) |
|||
ORF018786 | ABM | 1.0 ug DNA | EUR 486 |
Eif2c1 ORF Vector (Mouse) (pORF) |
|||
ORF043747 | ABM | 1.0 ug DNA | EUR 607.2 |
Eif2c2 ORF Vector (Mouse) (pORF) |
|||
ORF043748 | ABM | 1.0 ug DNA | EUR 607.2 |
Eif2c3 ORF Vector (Mouse) (pORF) |
|||
ORF043749 | ABM | 1.0 ug DNA | EUR 607.2 |
Eif2c4 ORF Vector (Mouse) (pORF) |
|||
ORF043750 | ABM | 1.0 ug DNA | EUR 607.2 |
EIF2C2 ORF Vector (Human) (pORF) |
|||
ORF003459 | ABM | 1.0 ug DNA | EUR 114 |
EIF2C2 ORF Vector (Human) (pORF) |
|||
ORF003460 | ABM | 1.0 ug DNA | EUR 114 |
EIF2C3 ORF Vector (Human) (pORF) |
|||
ORF003461 | ABM | 1.0 ug DNA | EUR 114 |
EIF2C1 3'UTR GFP Stable Cell Line |
|||
TU056714 | ABM | 1.0 ml | EUR 2799.6 |
EIF2C2 3'UTR GFP Stable Cell Line |
|||
TU056715 | ABM | 1.0 ml | EUR 1825.2 |
EIF2C3 3'UTR GFP Stable Cell Line |
|||
TU056716 | ABM | 1.0 ml | EUR 1672.8 |
EIF2C4 3'UTR GFP Stable Cell Line |
|||
TU056717 | ABM | 1.0 ml | EUR 2799.6 |
Eif2c1 3'UTR GFP Stable Cell Line |
|||
TU253872 | ABM | 1.0 ml | Ask for price |
Eif2c2 3'UTR GFP Stable Cell Line |
|||
TU253873 | ABM | 1.0 ml | Ask for price |
Eif2c3 3'UTR GFP Stable Cell Line |
|||
TU253874 | ABM | 1.0 ml | Ask for price |
Eif2c4 3'UTR GFP Stable Cell Line |
|||
TU253875 | ABM | 1.0 ml | Ask for price |
Eif2c1 3'UTR GFP Stable Cell Line |
|||
TU155704 | ABM | 1.0 ml | Ask for price |
Eif2c2 3'UTR GFP Stable Cell Line |
|||
TU155705 | ABM | 1.0 ml | Ask for price |
Eif2c3 3'UTR GFP Stable Cell Line |
|||
TU155706 | ABM | 1.0 ml | Ask for price |
Eif2c4 3'UTR GFP Stable Cell Line |
|||
TU155707 | ABM | 1.0 ml | Ask for price |
Lenti ORF clone of Eif2c4 (mGFP-tagged ORF) - Rat eukaryotic translation initiation factor 2C, 4 (Eif2c4), (10 ug) |
|||
RR215671L4 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Eif2c2 (mGFP-tagged ORF) - Rat eukaryotic translation initiation factor 2C, 2 (Eif2c2), (10 ug) |
|||
RR210245L4 | Origene Technologies GmbH | 10 µg | Ask for price |
EIF2C4 Blocking Peptide |
|||
33R-1952 | Fitzgerald | 100 ug | EUR 119 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of EIF2C4 antibody, catalog no. 70R-3041 |
EIF2C3 Blocking Peptide |
|||
33R-5810 | Fitzgerald | 100 ug | EUR 119 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of EIF2C3 antibody, catalog no. 70R-2539 |
EIF2C1 Blocking Peptide |
|||
33R-5890 | Fitzgerald | 100 ug | EUR 119 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of EIF2C1 antibody, catalog no. 70R-3471 |
Eif2c3 Blocking Peptide |
|||
33R-9576 | Fitzgerald | 100 ug | EUR 119 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Eif2c3 antibody, catalog no. 70R-9606 |
EIF2C3 Blocking Peptide |
|||
DF9508-BP | Affbiotech | 1mg | EUR 234 |
Lenti ORF clone of Eif2c4 (Myc-DDK-tagged ORF) - Rat eukaryotic translation initiation factor 2C, 4 (Eif2c4), (10 ug) |
|||
RR215671L3 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Eif2c2 (Myc-DDK-tagged ORF) - Rat eukaryotic translation initiation factor 2C, 2 (Eif2c2), (10 ug) |
|||
RR210245L3 | Origene Technologies GmbH | 10 µg | Ask for price |
Anti-Ago2/eIF2C2 Antibody |
|||
PB9978 | BosterBio | 100ug/vial | EUR 352.8 |
EIF3C |
|||
CSB-CL857867HU | Cusabio | 10 μg plasmid + 200μl Glycerol | Ask for price |
EIF2C3/ Argonaute 3 Antibody |
|||
49234 | SAB | 100ul | EUR 499 |
EIF2C3/ Argonaute 3 Antibody |
|||
49234-100ul | SAB | 100ul | EUR 399.6 |
EIF2C3/ Argonaute 3 Antibody |
|||
49234-50ul | SAB | 50ul | EUR 286.8 |
EIF2C2 Polyclonal Antibody |
|||
30692 | SAB | 100ul | EUR 439 |
EIF2C2 Polyclonal Antibody |
|||
30692-100ul | SAB | 100ul | EUR 302.4 |
EIF2C2 Polyclonal Antibody |
|||
30692-50ul | SAB | 50ul | EUR 224.4 |
EIF2C2 Polyclonal Antibody |
|||
30735 | SAB | 100ul | EUR 439 |
EIF2C2 Polyclonal Antibody |
|||
30735-100ul | SAB | 100ul | EUR 302.4 |
EIF2C2 Polyclonal Antibody |
|||
30735-50ul | SAB | 50ul | EUR 224.4 |
EIF2C1-Specific Antibody |
|||
abx232697-100ug | Abbexa | 100 ug | EUR 577.2 |
EIF2C3-Specific Antibody |
|||
abx232698-100ug | Abbexa | 100 ug | EUR 577.2 |
EIF2C2 Polyclonal Antibody |
|||
E96802a | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
EIF2C1 Protein Vector (Rat) (pPM-C-HA) |
|||
PV265760 | ABM | 500 ng | EUR 1429.2 |
EIF2C2 Protein Vector (Rat) (pPM-C-HA) |
|||
PV265764 | ABM | 500 ng | EUR 1399.2 |
EIF2C4 Protein Vector (Rat) (pPM-C-HA) |
|||
PV265768 | ABM | 500 ng | EUR 723.6 |
EIF2C2 Polyclonal Antibody |
|||
A72892 | EpiGentek | 50 μl | EUR 408 |
EIF2C2 Polyclonal Antibody |
|||
A72893 | EpiGentek | 50 μl | EUR 408 |
EIF2C1-Specific Antibody |
|||
abx232697-100g | Abbexa | 100 µg | EUR 350 |
EIF2C2 ELISA Kit (Bovine) (OKEH03983) |
|||
OKEH03983 | Aviva Systems Biology | 96 Wells | EUR 1012.8 |
Description: Description of target: ;Species reactivity: Bovine;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 6 pg/mL |
EIF2C1 Protein Vector (Rat) (pPB-C-His) |
|||
PV265758 | ABM | 500 ng | EUR 1429.2 |
EIF2C1 Protein Vector (Rat) (pPB-N-His) |
|||
PV265759 | ABM | 500 ng | EUR 1429.2 |
EIF2C1 Protein Vector (Rat) (pPM-C-His) |
|||
PV265761 | ABM | 500 ng | EUR 1429.2 |
EIF2C2 Protein Vector (Rat) (pPB-C-His) |
|||
PV265762 | ABM | 500 ng | EUR 1399.2 |
EIF2C2 Protein Vector (Rat) (pPB-N-His) |
|||
PV265763 | ABM | 500 ng | EUR 1399.2 |
EIF2C2 Protein Vector (Rat) (pPM-C-His) |
|||
PV265765 | ABM | 500 ng | EUR 1399.2 |
EIF2C4 Protein Vector (Rat) (pPB-C-His) |
|||
PV265766 | ABM | 500 ng | EUR 723.6 |
EIF2C4 Protein Vector (Rat) (pPB-N-His) |
|||
PV265767 | ABM | 500 ng | EUR 723.6 |
EIF2C4 Protein Vector (Rat) (pPM-C-His) |
|||
PV265769 | ABM | 500 ng | EUR 723.6 |
Human Protein argonaute-2 (EIF2C2) |
|||
1-CSB-EP891731HU | Cusabio |
|
|
Description: Recombinant Human Protein argonaute-2(EIF2C2) ,partial expressed in E.coli |
anti- EIF2C1-Specific antibody |
|||
FNab02697 | FN Test | 100µg | EUR 606.3 |
Description: Antibody raised against EIF2C1-Specific |
anti- EIF2C3-Specific antibody |
|||
FNab02698 | FN Test | 100µg | EUR 606.3 |
Description: Antibody raised against EIF2C3-Specific |
EIF2C2 Protein Vector (Human) (pPM-C-HA) |
|||
PV013835 | ABM | 500 ng | EUR 394.8 |
EIF2C2 Protein Vector (Human) (pPM-C-HA) |
|||
PV013839 | ABM | 500 ng | EUR 394.8 |
EIF2C3 Protein Vector (Human) (pPM-C-HA) |
|||
PV013843 | ABM | 500 ng | EUR 394.8 |
EIF2C1 Protein Vector (Human) (pPM-C-HA) |
|||
PV075139 | ABM | 500 ng | EUR 973.2 |
EIF2C4 Protein Vector (Human) (pPM-C-HA) |
|||
PV075143 | ABM | 500 ng | EUR 973.2 |
EIF2C1 Protein Vector (Mouse) (pPM-C-HA) |
|||
PV174988 | ABM | 500 ng | EUR 1278 |
EIF2C2 Protein Vector (Mouse) (pPM-C-HA) |
|||
PV174992 | ABM | 500 ng | EUR 1278 |
EIF2C3 Protein Vector (Mouse) (pPM-C-HA) |
|||
PV174996 | ABM | 500 ng | EUR 1278 |
EIF2C4 Protein Vector (Mouse) (pPM-C-HA) |
|||
PV175000 | ABM | 500 ng | EUR 1278 |
AGO3 Antibody / Argonaute-3 / eIF2C3 |
|||
V9391-100UG | NSJ Bioreagents | 100ug | EUR 349.3 |
Description: This antigen is involved in binding and translation repression of short RNAs. This antigen is also known as Argonaute RISC catalytic component 3. Required for RNA-mediated gene silencing (RNAi). Binds to short RNAs such as microRNAs (miRNAs) and represses the translation of mRNAs which are complementary to them. Proposed to be involved in stabilization of small RNA derivates (siRNA) derived from processed RNA polymerase III-transcribed Alu repeats containing a DR2 retinoic acid response element (RARE) in stem cells and in the subsequent siRNA-dependent degradation of a subset of RNA polymerase II-transcribed coding mRNAs by recruiting a mRNA decapping complex involving EDC4. Possesses RNA slicer activity but only on select RNAs bearing 5-flanking sequences to the region of guide-target complementarity. |
AGO3 Antibody / Argonaute-3 / eIF2C3 |
|||
V9391-20UG | NSJ Bioreagents | 20ug | EUR 153.3 |
Description: This antigen is involved in binding and translation repression of short RNAs. This antigen is also known as Argonaute RISC catalytic component 3. Required for RNA-mediated gene silencing (RNAi). Binds to short RNAs such as microRNAs (miRNAs) and represses the translation of mRNAs which are complementary to them. Proposed to be involved in stabilization of small RNA derivates (siRNA) derived from processed RNA polymerase III-transcribed Alu repeats containing a DR2 retinoic acid response element (RARE) in stem cells and in the subsequent siRNA-dependent degradation of a subset of RNA polymerase II-transcribed coding mRNAs by recruiting a mRNA decapping complex involving EDC4. Possesses RNA slicer activity but only on select RNAs bearing 5-flanking sequences to the region of guide-target complementarity. |
AGO3 Antibody / Argonaute-3 / eIF2C3 |
|||
V9391SAF-100UG | NSJ Bioreagents | 100ug | EUR 349.3 |
Description: This antigen is involved in binding and translation repression of short RNAs. This antigen is also known as Argonaute RISC catalytic component 3. Required for RNA-mediated gene silencing (RNAi). Binds to short RNAs such as microRNAs (miRNAs) and represses the translation of mRNAs which are complementary to them. Proposed to be involved in stabilization of small RNA derivates (siRNA) derived from processed RNA polymerase III-transcribed Alu repeats containing a DR2 retinoic acid response element (RARE) in stem cells and in the subsequent siRNA-dependent degradation of a subset of RNA polymerase II-transcribed coding mRNAs by recruiting a mRNA decapping complex involving EDC4. Possesses RNA slicer activity but only on select RNAs bearing 5-flanking sequences to the region of guide-target complementarity. |
EIF3C siRNA |
|||
20-abx915165 | Abbexa |
|
|
EIF3C siRNA |
|||
20-abx915166 | Abbexa |
|
|
EIF3C siRNA |
|||
20-abx901680 | Abbexa |
|
|
Rat Protein argonaute- 2, Eif2c2 ELISA KIT |
|||
ELI-24574r | Lifescience Market | 96 Tests | EUR 1063.2 |
EIF2C2 Protein Vector (Human) (pPB-C-His) |
|||
PV013833 | ABM | 500 ng | EUR 394.8 |
EIF2C2 Protein Vector (Human) (pPB-N-His) |
|||
PV013834 | ABM | 500 ng | EUR 394.8 |
EIF2C2 Protein Vector (Human) (pPM-C-His) |
|||
PV013836 | ABM | 500 ng | EUR 394.8 |
EIF2C2 Protein Vector (Human) (pPB-C-His) |
|||
PV013837 | ABM | 500 ng | EUR 394.8 |
EIF2C2 Protein Vector (Human) (pPB-N-His) |
|||
PV013838 | ABM | 500 ng | EUR 394.8 |
EIF2C2 Protein Vector (Human) (pPM-C-His) |
|||
PV013840 | ABM | 500 ng | EUR 394.8 |
EIF2C3 Protein Vector (Human) (pPB-C-His) |
|||
PV013841 | ABM | 500 ng | EUR 394.8 |
EIF2C3 Protein Vector (Human) (pPB-N-His) |
|||
PV013842 | ABM | 500 ng | EUR 394.8 |
EIF2C3 Protein Vector (Human) (pPM-C-His) |
|||
PV013844 | ABM | 500 ng | EUR 394.8 |
EIF2C1 Protein Vector (Human) (pPB-C-His) |
|||
PV075137 | ABM | 500 ng | EUR 973.2 |
EIF2C1 Protein Vector (Human) (pPB-N-His) |
|||
PV075138 | ABM | 500 ng | EUR 973.2 |
EIF2C1 Protein Vector (Human) (pPM-C-His) |
|||
PV075140 | ABM | 500 ng | EUR 973.2 |
EIF2C4 Protein Vector (Human) (pPB-C-His) |
|||
PV075141 | ABM | 500 ng | EUR 973.2 |
EIF2C4 Protein Vector (Human) (pPB-N-His) |
|||
PV075142 | ABM | 500 ng | EUR 973.2 |
EIF2C4 Protein Vector (Human) (pPM-C-His) |
|||
PV075144 | ABM | 500 ng | EUR 973.2 |
EIF2C4 Protein Vector (Mouse) (pPM-C-His) |
|||
PV175001 | ABM | 500 ng | EUR 1278 |
EIF2C1 Protein Vector (Mouse) (pPB-C-His) |
|||
PV174986 | ABM | 500 ng | EUR 1278 |
EIF2C1 Protein Vector (Mouse) (pPB-N-His) |
|||
PV174987 | ABM | 500 ng | EUR 1278 |
Chronically, 5-BDBD remedy additionally conferred progressive restoration (p < .05) of motor stability and coordination utilizing a rotarod take a look at, in addition to diminished anxiety-like conduct over 30 days. Curiously, depressive-type conduct was not noticed in mice handled with 5-BDBD for Three days. As well as, circulation cytometric evaluation revealed that 5-BDBD remedy decreased the overall variety of infiltrated leukocytes, and amongst these infiltrated leukocytes, pro-inflammatory cells of myeloid origin have been particularly diminished. 5-BDBD remedy diminished the cell floor expression of P2X4R in circulation cytometry-sorted monocytes and microglia with out lowering the overall P2X4R stage in mind tissue.
In abstract, acute P2X4R inhibition protects towards ischemic damage at each acute and power time-points after stroke. Diminished numbers of infiltrating pro-inflammatory myeloid cells, decreased floor P2X4R expression, and diminished BBB disruption are seemingly its mechanism of neuroprotection and neuro-rehabilitation.